Holen Sie sich die Stockscreener-App
12.37
2.38%
-0.2496
Oric Pharmaceuticals Inc Aktie (ORIC) Neueste Nachrichten
Oric Pharmaceuticals joins 2026 Cantor Global Healthcare Conference fireside chat: Can ORIC break above $12.51? - Traders Union
Enterprise value to revenue forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC - TradingView
Enterprise value to revenue forward of Oric Pharmaceuticals, Inc. – MUN:4TZ - TradingView
ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses - Stocktwits
ORIC stock holds steady as biotech eyes next trial and earnings - AD HOC NEWS
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Oric Pharmaceuticals Inc (NYSE: ORIC) Share Price, ORIC Stock News, ORIC Share Price & Updates - Kalkine
Himalayas-1: Bayer and ORIC Double Down on Prostate Cancer With New Phase 3 Combo Trial - TipRanks
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - Yahoo Finance
ORIC stock holds firm as biotech valuation nears 0.93 billion USD - AD HOC NEWS
(ORIC) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Oric Pharmaceuticals stock holds above $13 as BlackRock boosts stake - AD HOC NEWS
Oric Pharmaceuticals (NASDAQ: ORIC) CFO sells 77,000 shares - Stock Titan
ORIC Pharmaceuticals (NASDAQ: ORIC) officer plans $3.1M stock sale - Stock Titan
Blue Owl Capital Holdings LP Invests $4.33 Million in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Oric Pharmaceuticals (NASDAQ:ORIC) Sets New 12-Month HighHere's Why - MarketBeat
Oric (ORIC) Earnings Report: EPS Misses Its Estimate in Latest Trading; After Earnings: The Stock Gains 4.04% in the Latest SessionForward EPS Estimate - vinanet.vn
BCAX Stock Price and Chart — NASDAQ:BCAX - TradingView
HC Wainwright Issues Pessimistic Outlook for ORIC Earnings - MarketBeat
Understanding Momentum Shifts in (ORIC) - Stock Traders Daily
ORIC Pharmaceuticals (ORIC) Slips 1.17% as Biotech Stock Approaches Key Support at $12.89Vanna Flow - dars.gov.et
Price to book forward of Oric Pharmaceuticals, Inc. – HAM:4TZ - TradingView
What is HC Wainwright's Forecast for ORIC Q1 Earnings? - MarketBeat
ORIC Pharmaceuticals, Inc. (ORIC) options chain - Yahoo Finance Australia
ORIC PHARMACEUTICALS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $27 FROM $25 - webull.com
ORIC Maintained by HC Wainwright & Co. -- Price Target Raised to $27 - GuruFocus
H.C. Wainwright raises ORIC Pharmaceuticals price target to $27 on pipeline progress - Investing.com
H.C. Wainwright Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Raises Target Price to $27 - Moomoo
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
ORIC Pharmaceuticals (ORIC) Q2 Losses Put Valuation In Focus As Shares Rally - Sahm
Dimensional Fund Advisors LP Boosts Holdings in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Is ORIC Pharmaceuticals' (ORIC) Equity-Funded ESOP Masking or Clarifying Its Widening Net Losses? - Yahoo Finance
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: A Promising Biotech with 60% Upside Potential - DirectorsTalk Interviews
Oric Pharmaceuticals Inc (ORIC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Do ORIC Pharmaceuticals’ Widening Losses But Lower Per-Share Losses Reveal a Strategic Trade-Off for ORIC? - Sahm
A Quick Look at Today's Ratings for Oric Pharmaceuticals(ORIC.US), With a Forecast Between $14 to $25 - Moomoo
Oric Pharmaceuticals (NASDAQ:ORIC) Trading 12.3% HigherHere's What Happened - MarketBeat
Stock Traders Purchase High Volume of Put Options on Oric Pharmaceuticals (NASDAQ:ORIC) - MarketBeat
Oric Pharmaceuticals (ORIC) Projected to Release Earnings on Tuesday - MarketBeat
ORIC SWOT Analysis: Key Insights from the 10-Q Filing - GuruFocus
ORIC Pharmaceuticals (ORIC) Launches Pivotal Phase 3 Trial Amid Mixed Market Signals - GuruFocus
Oric Pharmaceuticals, Inc. 6M 2026: Net loss $(77.3M), Diluted EPS $(0.72) — 10-Q Summary - TradingView
ORIC: Net loss rose to $77.3M as R&D spending increased; cash runway extends into H2 2028 - TradingView
ORIC: Advanced late-stage oncology pipeline with strong cash position and key trials underway - TradingView
Oric Pharmaceuticals reports Q2 2026 net loss $41.5M, cash $387.6M; Phase 3 trial initiated - TradingView
ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates - The Manila Times
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 5.2%Should You Sell? - MarketBeat
ORIC Pharmaceuticals starts Phase 3 trial for p... - Pluang
Avoiding Lag: Real-Time Signals in (ORIC) Movement - Stock Traders Daily
Oric Pharmaceuticals Expands Inducement Equity Incentive Plan - The Globe and Mail
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: 77.77% Potential Upside Beckons Biotech Investors - DirectorsTalk Interviews
Vivo Capital LLC Cuts Stake in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
ORIC Pharmaceuticals Director Richard Heyman Reports Major Stock Transactions on July 24, 2026 - Kalkine Media
Oric Pharmaceuticals Inc (ORIC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Oric Pharmaceuticals Inc (ORIC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oric Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ORIC - TradingView
Oric Pharmaceuticals Inc (ORIC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Oric Pharmaceuticals Inc (ORIC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ORIC|Oric Pharmaceuticals Inc|Price:13.500|Chg%:+0.570 - TradingKey
Orbimed Advisors LLC Reduces Stock Holdings in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
ORIC|Oric Pharmaceuticals Inc|Price:12.100|Chg%:+1.210 - TradingKey
Oric Pharmaceuticals Inc (ORIC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):